相关实验视频

Updated: May 10, 2025

Use of Animal Model of Sepsis to Evaluate Novel Herbal Therapies

Use of Animal Model of Sepsis to Evaluate Novel Herbal Therapies

Published on: April 11, 2012

博苏替尼在实验性败血症中减轻炎症

C M C Cunha^1,2, V H P Abreu^1,2, V Estato¹

¹Laboratório de Imunofarmacologia, Instituto Oswaldo Cruz, FIOCRUZ, Rio de Janeiro, Brazil.

European journal of clinical investigation

|April 28, 2025

概括

博苏替尼 (bosutinib) 是Src家族的氨酸激酶抑制剂,在治疗败血症方面表现有前途. 这项研究发现,它减少了炎症,改善了生存率,并在毒症的小鼠模型中保护了器官.

科学领域:

免疫学免疫学免疫学
药理学药理学是指药理学的学科.
关键护理医学关键护理医学

背景情况:

败血症是一种全球性健康危机,死亡率高,治疗方法有限.
炎症,免疫细胞功能障碍和器官损伤是败血症病理生理学的特征.
Src家族氨酸激酶 (SFK) 是免疫反应和炎症的关键调节者.

研究的目的:

调查SFK抑制剂博苏替尼的治疗潜力,用于治疗败血症.
在实验性败血症中评估博苏替尼对炎症反应和器官功能的影响.

主要方法:

在小鼠中发生败血症的结和刺穿 (CLP) 模型.
用博苏替尼 (3毫克/千克) 或载体控制治疗.
评估临床症状,生存,炎症标志物,细胞透,肺功能和大脑微循环.

主要成果:

博苏替尼显著改善了生存率,并减少了败血症的严重程度.
治疗降低了促炎性细胞因子,化学因子和细菌负载.
博苏替尼减轻了肺损伤,通过增强血液流动和减少白细胞粘附,改善了大脑的微循环.

结论:

在实验性败血症中,博苏替尼前期治疗有效减弱了全身和神经血管炎症反应.
用博苏替尼 (bosutinib) 准SFK为败血症提供了一个潜在的治疗策略.

关键词:

Src家族的氨酸激酶抑制剂.波苏丁尼布 (Bosutinib) 是一种神经炎症是一种神经炎症.这是一种血症.

更多相关视频

Cecal Ligation Puncture Procedure

Cecal Ligation Puncture Procedure

Published on: May 7, 2011

Design of Cecal Ligation and Puncture and Intranasal Infection Dual Model of Sepsis-Induced Immunosuppression

Design of Cecal Ligation and Puncture and Intranasal Infection Dual Model of Sepsis-Induced Immunosuppression

Published on: June 15, 2019

相关概念视频

The JAK-STAT Signaling Pathway

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...